Press Releases Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 20/01/2026 GMT			5-day change	1st Jan Change
331.00 ^USD	+0.18%		+2.07%	+1.13%

01-20	Global drugmakers rush to boost US presence as tariff threat looms	RE
01-15	Espiria Hållbar Framtid Rises 0.4 Percent in December — Increased Holdings in Epiroc and Afry	FW

Press Releases

01-12	Amgen : 2026 JP Morgan Healthcare Conference Presentation (01.12.26 0900AM)	PU
01-07	AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE	PR
01-06	AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE	PR
12-31	UPC Aligns With The EPO In Allowing Functional Antibody Claims	AQ
12-19	AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS	PR
12-11	FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS	PR
12-09	AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND	PR
12-08	Formulation Fight: Amgen Case Tests Patentability Of Biopharmaceuticals In India	AQ
11-26	Real-World Evidence [RWE] Demonstrates Repatha's Long-Term Cardiovascular Benefits	AQ
11-26	FDA Approves Accord BioPharma's Denosumab Biosimilars	AQ
11-24	AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE	PR
11-24	AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE	PR
11-24	Regeneron Moves To Strike And Dismiss Amgen's Counterclaims In Aflibercept Litigation	AQ
11-19	FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER	PR
11-08	AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL	PR
11-05	FDA Grants Interchangeability Designation To Fresenius Kabi's And Celltrion's Denosumab Biosimilars	AQ
11-04	Amgen : Q3 2025 - Earnings Call Slides - FINAL	PU
11-04	Amgen: Q3 Earnings Snapshot	AQ
11-04	AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS	PR
31/10/25	AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND	PR
31/10/25	Amgen : Breaks Ground on $600 Million Center for Science and Innovation in Thousand Oaks, Calif.	PU
31/10/25	AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025	PR
29/10/25	AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS	PR
23/10/25	Halper Sadeh LLC Encourages Amgen Inc. Shareholders to Contact the Firm to Discuss Their Rights	BU
22/10/25	Honoring Peggy: Emily Razaqi Shares a Personal Story for Breast Cancer Awareness Month	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Amgen Inc.

Equities

AMGN

US0311621009

Pharmaceuticals

Press Releases

Filters